Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
作者： S O'Reilly , G F Fleming , S D Barker , J R Walczak , M A Bookman
DOI: 10.1200/JCO.1997.15.1.177
关键词:
摘要: PURPOSEA phase I and pharmacologic study to evaluate the feasibility of administering paclitaxel (PTX) in combination with topotecan (TPT) without granulocyte colony-stimulating factor (G-CSF) women recurrent or refractory ovarian cancer.PATIENTS AND METHODSTPT was administered as a 30-minute infusion daily for 5 days PTX given 24-hour (PTX-24) either before TPT on day 1 after 5. Each patient received both schedules an alternating basis every 3 weeks. Sequential dose escalation PTX-24 G-CSF resulted five dosage permutations TPT/PTX (mg/ m2): 0.75/135 0.75/135, 1.25/135, 1.50/135, 1.25/170 G-CSF.RESULTSTwenty-two patients 109 courses therapy. Dose-limiting myelosuppression consistently occurred at first TPT/PTX-24 level (0.75/135 mg/m2) absence support. Although addition reduced rates complicated neutropenia, incidences d...
elsevier.com
sci-hub.se 参考文章(24)
A Y Chen, L F Liu, DNA Topoisomerases: Essential Enzymes and Lethal Targets Annual Review of Pharmacology and Toxicology. ,vol. 34, pp. 191- 218 ,(1994) , 10.1146/ANNUREV.PA.34.040194.001203
E. C. Kohn, G. Sarosy, A. Bicher, C. Link, M. Christian, S. M. Steinberg, M. Rothenberg, D. O. Adamo, P. Davis, F. P. Ognibene, R. E. Cunnion, E. Reed, Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. Journal of the National Cancer Institute. ,vol. 86, pp. 18- 24 ,(1994) , 10.1093/JNCI/86.1.18
Yves Pommier, D. Pharm, Mark R. Fesen, Akira Fujimori, Richard Bertrand, Eric Solary, Glenda Kohlhagen, Kurt W. Kohn, Cellular Determinants of Sensitivity and Resistance to DNA Topoisomerase Inhibitors Cancer Investigation. ,vol. 12, pp. 530- 542 ,(1994) , 10.3109/07357909409021413
Milan Potmesil, Camptothecins: From Bench Research to Hospital Wards Cancer Research. ,vol. 54, pp. 1431- 1439 ,(1994)
E K Rowinsky, A Adjei, R C Donehower, S D Gore, R J Jones, P J Burke, Y C Cheng, L B Grochow, S H Kaufmann, Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. Journal of Clinical Oncology. ,vol. 12, pp. 2193- 2203 ,(1994) , 10.1200/JCO.1994.12.10.2193
J T Thigpen, J A Blessing, H Ball, S J Hummel, R J Barrett, Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. Journal of Clinical Oncology. ,vol. 12, pp. 1748- 1753 ,(1994) , 10.1200/JCO.1994.12.9.1748
A I Einzig, P H Wiernik, J Sasloff, C D Runowicz, G L Goldberg, Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. Journal of Clinical Oncology. ,vol. 10, pp. 1748- 1753 ,(1992) , 10.1200/JCO.1992.10.11.1748
A A Miller, R C Lilenbaum, T J Lynch, G L Rosner, M J Ratain, M R Green, R L Schilsky, Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. Journal of Clinical Oncology. ,vol. 14, pp. 1964- 1965 ,(1996) , 10.1200/JCO.1996.14.6.1964
Hagop M Kantarjian, Miloslav Beran, Amy Ellis, Leonard Zwelling, Susan O'Brien, Lorraine Cazenave, Charles Koller, Mary Beth Rios, William Plunkett, Michael J Keating, Elihu H Estey, Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia Blood. ,vol. 81, pp. 1146- 1151 ,(1993) , 10.1182/BLOOD.V81.5.1146.BLOODJOURNAL8151146
E K Rowinsky, M R Gilbert, W P McGuire, D A Noe, L B Grochow, A A Forastiere, D S Ettinger, B G Lubejko, B Clark, S E Sartorius, Sequences of Taxol and Cisplatin: A Phase I and Pharmacologic Study Journal of Clinical Oncology. ,vol. 9, pp. 1692- 1703 ,(1991) , 10.1200/JCO.1991.9.9.1692